TT:NYSETrane Technologies plc Analysis
Data as of 2026-03-10 - not real-time
$427.52
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Trane Technologies (TT) is trading at $427.52, which sits just above its 50‑day (456.37) and 200‑day (422.59) SMAs but below the 20‑day SMA, indicating a short‑term pullback within a longer‑term uptrend. The 14‑day RSI of 41.9 and a bearish MACD histogram (‑6.59) reinforce the near‑term downside pressure, while volume is increasing, suggesting that the recent sell‑off is supported by market participation. Volatility remains elevated at 36.6% over the past 30 days, yet the beta of 0.89 points to lower systematic risk than the broader market. Fundamentally, TT delivers strong profitability with a 13.7% profit margin, 36.0% ROE, and 5.6% revenue growth, while maintaining a healthy operating cash flow of $3.19B. The forward P/E of 25.4 is well below the current trailing P/E of 32.1 and the industry average of 29.5, indicating earnings acceleration. Dividend sustainability looks solid, highlighted by a recent 12% increase to $1.05 per quarter and a modest payout ratio of 28.6%. Analyst sentiment is bullish, with a consensus “Buy” rating, a median target of $470 and an implied upside of about 12% from today’s price. Institutional ownership exceeds 50%, and recent coverage from Oppenheimer raised the price objective to $468, reinforcing confidence in the stock’s medium‑term trajectory.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and RSI near neutral suggest limited upside
- Increasing volume confirms short‑term selling pressure
- Dividend increase provides downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Forward P/E compression and earnings growth
- Analyst price targets imply ~12% upside
- Strong cash flow and high ROE support valuation
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Climate‑focused product portfolio drives secular demand
- Sustained dividend growth and low beta reduce risk
- Robust balance sheet with manageable leverage
Key Metrics & Analysis
Financial Health
Revenue Growth5.60%
Profit Margin13.69%
P/E Ratio32.1
ROE36.96%
ROA11.64%
Debt/Equity63.25
P/B Ratio11.0
Op. Cash Flow$3.2B
Free Cash Flow$1.9B
Industry P/E29.5
Technical Analysis
TrendNeutral
RSI41.9
Support$413.98
Resistance$479.37
MA 20$456.37
MA 50$422.26
MA 200$422.59
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89
Valuation
Fair Value$137.05
Target Price$479.73
Upside/Downside12.21%
GradeFair
TypeBlend
Dividend Yield0.99%
Risk Assessment
Beta0.89
Volatility36.60%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.